NY-AQARA
9.4.2024 09:01:58 CEST | Business Wire | Press release
Aqara, a leading provider of smart home solutions, today announced the availability of the Motion and Light Sensor P2, its new generation motion sensor built upon the Thread protocol and the industry-unifying Matter standard. The native Matter connectivity offers unparalleled compatibility across smart home platforms including Amazon Alexa, Apple Home, Google Home, and Samsung SmartThings1. With Matter's local networking capabilities, the P2 sensor ensures enhanced responsiveness and reliability.
“In the rapidly expanding global market for Passive Infrared (PIR) sensors, Aqara has achieved remarkable success, distributing over 100,000 units last year,” states Cathy You, Aqara Senior Vice President, Global Business and Strategy. “The launch of the Motion and Light Sensor P2, which combines our renowned sensor technology with the latest in connectivity protocols and standards, encapsulates our forward-thinking approach and our commitment to delivering smart home solutions that are ready for tomorrow's advancement.”
The Motion and Light Sensor P2 integrates an ultra-wide angle PIR motion sensor with a standalone illumination sensor, providing precise detection up to 7 meters (ca. 23 feet) and 170° horizontally2. This facilitates a range of use scenarios from automated lighting and security enhancement to climate control. The sensor also measures light intensity independently of motion detection3, enabling sophisticated lighting and window covering control for optimal comfort and energy efficiency. Engineered for longevity, the Motion and Light Sensor P2 boasts a robust battery life of up to two years, ensuring dependable operation with minimal maintenance.
As a Thread-enabled device, the Motion and Light Sensor P2 connects to any Matter controller with Thread Border Router functionality, and allows use across multiple compatible platforms thanks to Matter's multi-admin feature. Furthermore, the sensor offers a few Aqara Home exclusive features such as customizable sensitivity and detection timeout settings for tailored performance4. Users can fine-tune both parameters through the Aqara Home app, which requires Aqara's own Thread-enabled Matter controller, for example the upcoming Hub M3.
As part of Aqara’s expanding Thread-enabled product line, the Motion and Light Sensor P2 exemplifies the Company’s dedication to elevating smart home experiences through enhanced interoperability and simplicity. Additional Thread devices from Aqara are expected in the coming months, including the aforementioned Hub M3 and the retrofit home access solution Smart Lock U200.
The Motion and Light Sensor P2 is now available in Aqara’s Amazon brand stores in North America (US, Canada), Europe (France, Germany, Italy, Poland, Spain, UK) and Asia (Japan), as well as through select Aqara retailers worldwide5.
For more information on this sensor, please visit our website.
1. A Matter controller with Thread Border Router functionality is required for the connection to the corresponding Matter-enabled system.
2. Based on the internal lab test, measured under the ambient temperature of 25 °C (ca. 77 °F) and high sensitivity level.
3. Illumination sensing functionality is not available on Alexa at the time of launch.
4. By default, the sensor is set to medium sensitivity and a 30-second detection timeout.
5. Product availability may vary by retail channel.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409809799/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom